MCRB Seres Therapeutics
- 0.708
- -0.002-0.30%
- 0.692
- -0.017-2.36%
Seres Therapeutics News
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity Under Strategic Partnership With Pfizer
Flagship Pioneering and ProFound Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a...
12 Health Care Stocks Moving In Monday's Intraday Session
GainersSeres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. Renovaro (NASDAQ:RENB) shares increase
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of GameStop Corp. (NYSE:GME) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to sell up to 75 million shares.
12 Health Care Stocks Moving In Friday's Intraday Session
GainersVenus Concept (NASDAQ:VERO) shares rose 87.9% to $1.1 during Friday's regular session. The company's market cap stands at $7.0 million. Asensus Surgical (AMEX:ASXC) stock moved upwards by 41.22
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Seres Therapeutics, Lowers Price Target to $10
Seres Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/07/2024 1104.82% Canaccord Genuity $15 → $10 Maintains Buy 05/09/2024 381.93% Oppenheimer $5 → $4 Maint
Oppenheimer Downgrades Seres Therapeutics(MCRB.US) to Hold Rating
Oppenheimer analyst Jeff Jones downgrades $Seres Therapeutics(MCRB.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 40.6% and a total average return of 20.7% over th
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Cuts Target Price to $10
CCORF analyst John Newman maintains $Seres Therapeutics(MCRB.US)$ with a buy rating, and adjusts the target price from $15 to $10.According to TipRanks data, the analyst has a success rate of 39.0% an
Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target
Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target.
Express News | Seres Therapeutics : Oppenheimer Cuts to Perform From Outperform
Chardan Adjusts PT on Seres Therapeutics to $1.25 From $6 on Heels of Announced MoU With Nestle for Sale of VOWST Assets; Maintains Buy Rating
Chardan Adjusts PT on Seres Therapeutics to $1.25 From $6 on Heels of Announced MoU With Nestle for Sale of VOWST Assets; Maintains Buy Rating.
Nestlé Unit to Buy Vowst Assets From Seres Therapeutics
Seres Therapeutics entered a nonbinding memorandum of understanding to divest its clostridioides difficile infection treatment Vowst to Swiss conglomerate Nestlé's (NESN.SW) nutritional science unit.
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced tha
Express News | Seres Therapeutics Inc : Chardan Capital Markets Cuts Target Price to $1.25 From $6
Chardan Capital Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Cuts Target Price to $1.25
Chardan Capital analyst Keay Nakae maintains $Seres Therapeutics(MCRB.US)$ with a buy rating, and adjusts the target price from $6 to $1.25.According to TipRanks data, the analyst has a success rate o
Sector Update: Health Care Stocks Advance Thursday Afternoon
Health care stocks rose Thursday afternoon with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) eased 0.2%. In cor
Seres Therapeutics Shares Are Lower Higher After the Company Entered a Memorandum of Understanding With Nestlé Health Science for the Sale of Its VOWST Assets. The Stock Initially Traded Higher, but It Has Since Reversed.
Seres Therapeutics Shares Are Lower Higher After the Company Entered a Memorandum of Understanding With Nestlé Health Science for the Sale of Its VOWST Assets. The Stock Initially Traded Higher, but
Express News | Shares of Seres Therapeutics Down 3.5% Premarket After Nestle's Health Arm to Buy Co's Bacterial Infection Drug
Nestlé to Buy Microbiome Therapy Vowst From Seres
Analysis
Price Target
No Data
